OptiNose (OPTN) Trading Up 7.5%

OptiNose Inc (NASDAQ:OPTN)’s share price was up 7.5% during trading on Tuesday . The company traded as high as $8.61 and last traded at $8.60. Approximately 729,967 shares traded hands during trading, an increase of 399% from the average daily volume of 146,336 shares. The stock had previously closed at $8.00.

A number of equities analysts recently commented on OPTN shares. Cantor Fitzgerald reiterated a “buy” rating and set a $27.00 price target on shares of OptiNose in a report on Monday, February 4th. ValuEngine cut OptiNose from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Zacks Investment Research upgraded OptiNose from a “sell” rating to a “hold” rating in a report on Tuesday, January 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $28.75.

Get OptiNose alerts:

The company has a quick ratio of 10.13, a current ratio of 10.44 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $329.84 million, a P/E ratio of -1.53 and a beta of 0.48.

In other news, CEO Peter K. Miller acquired 10,000 shares of OptiNose stock in a transaction dated Thursday, December 13th. The stock was bought at an average price of $7.68 per share, for a total transaction of $76,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Joseph C. Scodari acquired 6,430 shares of OptiNose stock in a transaction dated Wednesday, December 12th. The shares were purchased at an average price of $7.89 per share, with a total value of $50,732.70. The disclosure for this purchase can be found here. Insiders own 67.80% of the company’s stock.

Several large investors have recently modified their holdings of OPTN. FMR LLC raised its position in shares of OptiNose by 1.1% in the third quarter. FMR LLC now owns 6,183,095 shares of the company’s stock valued at $76,856,000 after buying an additional 65,887 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of OptiNose by 39.1% in the third quarter. JPMorgan Chase & Co. now owns 1,874,231 shares of the company’s stock valued at $23,297,000 after buying an additional 526,501 shares in the last quarter. BlackRock Inc. raised its position in shares of OptiNose by 69.0% in the fourth quarter. BlackRock Inc. now owns 1,820,167 shares of the company’s stock valued at $11,285,000 after buying an additional 743,369 shares in the last quarter. Foresite Capital Management IV LLC raised its position in shares of OptiNose by 17.1% in the fourth quarter. Foresite Capital Management IV LLC now owns 1,708,545 shares of the company’s stock valued at $10,593,000 after buying an additional 250,000 shares in the last quarter. Finally, Thrivent Financial for Lutherans raised its position in shares of OptiNose by 7.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,376,200 shares of the company’s stock valued at $8,532,000 after buying an additional 93,969 shares in the last quarter. Institutional investors own 52.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4199587/optinose-optn-trading-up-7-5.html.

About OptiNose (NASDAQ:OPTN)

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Featured Story: How mutual funds make money